12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vismodegib regulatory update

EMA accepted for review an MAA from Roche for vismodegib to treat adults with advanced basal cell carcinoma for whom surgery is considered inappropriate. The MAA submission triggered a $6...

Read the full 128 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >